Fragile X targeted pharmacotherapy: Lessons learned and future directions

Craig A. Erickson, Matthew H. Davenport, Tori L. Schaefer, Logan K. Wink, Ernest V. Pedapati, John A. Sweeney, Sarah E. Fitzpatrick, W. Ted Brown, Dejan Budimirovic, Randi J. Hagerman, David Hessl, Walter E. Kaufmann, Elizabeth Berry-Kravis

Research output: Contribution to journalReview article

Abstract

Our understanding of fragile X syndrome (FXS) pathophysiology continues to improve and numerous potential drug targets have been identified. Yet, current prescribing practices are only symptom-based in order to manage difficult behaviors, as no drug to date is approved for the treatment of FXS. Drugs impacting a diversity of targets in the brain have been studied in recent FXS-specific clinical trials. While many drugs have focused on regulation of enhanced glutamatergic or deficient GABAergic neurotransmission, compounds studied have not been limited to these mechanisms. As a single-gene disorder, it was thought that FXS would have consistent drug targets that could be modulated with pharmacotherapy and lead to significant improvement. Unfortunately, despite promising results in FXS animal models, translational drug treatment development in FXS has largely failed. Future success in this field will depend on learning from past challenges to improve clinical trial design, choose appropriate outcome measures and age range choices, and find readily modulated drug targets. Even with many negative placebo-controlled study results, the field continues to move forward exploring both the new mechanistic drug approaches combined with ways to improve trial execution. This review summarizes the known phenotype and pathophysiology of FXS and past clinical trial rationale and results, and discusses current challenges facing the field and lessons from which to learn for future treatment development efforts.

Original languageEnglish (US)
Article number7
JournalJournal of Neurodevelopmental Disorders
Volume9
Issue number1
DOIs
StatePublished - Jun 12 2017

Fingerprint

Drug Therapy
Fragile X Syndrome
Clinical Trials
Synaptic Transmission
Placebos
Outcome Assessment (Health Care)
Learning
Phenotype
Brain
Genes

Keywords

  • Drug development
  • Fragile X syndrome
  • Genetic disorder
  • Targeted treatments
  • Translational treatment

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Pathology and Forensic Medicine
  • Clinical Neurology
  • Cognitive Neuroscience

Cite this

Erickson, C. A., Davenport, M. H., Schaefer, T. L., Wink, L. K., Pedapati, E. V., Sweeney, J. A., ... Berry-Kravis, E. (2017). Fragile X targeted pharmacotherapy: Lessons learned and future directions. Journal of Neurodevelopmental Disorders, 9(1), [7]. DOI: 10.1186/s11689-017-9186-9

Fragile X targeted pharmacotherapy : Lessons learned and future directions. / Erickson, Craig A.; Davenport, Matthew H.; Schaefer, Tori L.; Wink, Logan K.; Pedapati, Ernest V.; Sweeney, John A.; Fitzpatrick, Sarah E.; Brown, W. Ted; Budimirovic, Dejan; Hagerman, Randi J.; Hessl, David; Kaufmann, Walter E.; Berry-Kravis, Elizabeth.

In: Journal of Neurodevelopmental Disorders, Vol. 9, No. 1, 7, 12.06.2017.

Research output: Contribution to journalReview article

Erickson, CA, Davenport, MH, Schaefer, TL, Wink, LK, Pedapati, EV, Sweeney, JA, Fitzpatrick, SE, Brown, WT, Budimirovic, D, Hagerman, RJ, Hessl, D, Kaufmann, WE & Berry-Kravis, E 2017, 'Fragile X targeted pharmacotherapy: Lessons learned and future directions' Journal of Neurodevelopmental Disorders, vol 9, no. 1, 7. DOI: 10.1186/s11689-017-9186-9
Erickson CA, Davenport MH, Schaefer TL, Wink LK, Pedapati EV, Sweeney JA et al. Fragile X targeted pharmacotherapy: Lessons learned and future directions. Journal of Neurodevelopmental Disorders. 2017 Jun 12;9(1). 7. Available from, DOI: 10.1186/s11689-017-9186-9

Erickson, Craig A.; Davenport, Matthew H.; Schaefer, Tori L.; Wink, Logan K.; Pedapati, Ernest V.; Sweeney, John A.; Fitzpatrick, Sarah E.; Brown, W. Ted; Budimirovic, Dejan; Hagerman, Randi J.; Hessl, David; Kaufmann, Walter E.; Berry-Kravis, Elizabeth / Fragile X targeted pharmacotherapy : Lessons learned and future directions.

In: Journal of Neurodevelopmental Disorders, Vol. 9, No. 1, 7, 12.06.2017.

Research output: Contribution to journalReview article

@article{b42726d9db9549488983e1883a708d7a,
title = "Fragile X targeted pharmacotherapy: Lessons learned and future directions",
abstract = "Our understanding of fragile X syndrome (FXS) pathophysiology continues to improve and numerous potential drug targets have been identified. Yet, current prescribing practices are only symptom-based in order to manage difficult behaviors, as no drug to date is approved for the treatment of FXS. Drugs impacting a diversity of targets in the brain have been studied in recent FXS-specific clinical trials. While many drugs have focused on regulation of enhanced glutamatergic or deficient GABAergic neurotransmission, compounds studied have not been limited to these mechanisms. As a single-gene disorder, it was thought that FXS would have consistent drug targets that could be modulated with pharmacotherapy and lead to significant improvement. Unfortunately, despite promising results in FXS animal models, translational drug treatment development in FXS has largely failed. Future success in this field will depend on learning from past challenges to improve clinical trial design, choose appropriate outcome measures and age range choices, and find readily modulated drug targets. Even with many negative placebo-controlled study results, the field continues to move forward exploring both the new mechanistic drug approaches combined with ways to improve trial execution. This review summarizes the known phenotype and pathophysiology of FXS and past clinical trial rationale and results, and discusses current challenges facing the field and lessons from which to learn for future treatment development efforts.",
keywords = "Drug development, Fragile X syndrome, Genetic disorder, Targeted treatments, Translational treatment",
author = "Erickson, {Craig A.} and Davenport, {Matthew H.} and Schaefer, {Tori L.} and Wink, {Logan K.} and Pedapati, {Ernest V.} and Sweeney, {John A.} and Fitzpatrick, {Sarah E.} and Brown, {W. Ted} and Dejan Budimirovic and Hagerman, {Randi J.} and David Hessl and Kaufmann, {Walter E.} and Elizabeth Berry-Kravis",
year = "2017",
month = "6",
doi = "10.1186/s11689-017-9186-9",
volume = "9",
journal = "Journal of Neurodevelopmental Disorders",
issn = "1866-1947",
publisher = "Springer New York",
number = "1",

}

TY - JOUR

T1 - Fragile X targeted pharmacotherapy

T2 - Journal of Neurodevelopmental Disorders

AU - Erickson,Craig A.

AU - Davenport,Matthew H.

AU - Schaefer,Tori L.

AU - Wink,Logan K.

AU - Pedapati,Ernest V.

AU - Sweeney,John A.

AU - Fitzpatrick,Sarah E.

AU - Brown,W. Ted

AU - Budimirovic,Dejan

AU - Hagerman,Randi J.

AU - Hessl,David

AU - Kaufmann,Walter E.

AU - Berry-Kravis,Elizabeth

PY - 2017/6/12

Y1 - 2017/6/12

N2 - Our understanding of fragile X syndrome (FXS) pathophysiology continues to improve and numerous potential drug targets have been identified. Yet, current prescribing practices are only symptom-based in order to manage difficult behaviors, as no drug to date is approved for the treatment of FXS. Drugs impacting a diversity of targets in the brain have been studied in recent FXS-specific clinical trials. While many drugs have focused on regulation of enhanced glutamatergic or deficient GABAergic neurotransmission, compounds studied have not been limited to these mechanisms. As a single-gene disorder, it was thought that FXS would have consistent drug targets that could be modulated with pharmacotherapy and lead to significant improvement. Unfortunately, despite promising results in FXS animal models, translational drug treatment development in FXS has largely failed. Future success in this field will depend on learning from past challenges to improve clinical trial design, choose appropriate outcome measures and age range choices, and find readily modulated drug targets. Even with many negative placebo-controlled study results, the field continues to move forward exploring both the new mechanistic drug approaches combined with ways to improve trial execution. This review summarizes the known phenotype and pathophysiology of FXS and past clinical trial rationale and results, and discusses current challenges facing the field and lessons from which to learn for future treatment development efforts.

AB - Our understanding of fragile X syndrome (FXS) pathophysiology continues to improve and numerous potential drug targets have been identified. Yet, current prescribing practices are only symptom-based in order to manage difficult behaviors, as no drug to date is approved for the treatment of FXS. Drugs impacting a diversity of targets in the brain have been studied in recent FXS-specific clinical trials. While many drugs have focused on regulation of enhanced glutamatergic or deficient GABAergic neurotransmission, compounds studied have not been limited to these mechanisms. As a single-gene disorder, it was thought that FXS would have consistent drug targets that could be modulated with pharmacotherapy and lead to significant improvement. Unfortunately, despite promising results in FXS animal models, translational drug treatment development in FXS has largely failed. Future success in this field will depend on learning from past challenges to improve clinical trial design, choose appropriate outcome measures and age range choices, and find readily modulated drug targets. Even with many negative placebo-controlled study results, the field continues to move forward exploring both the new mechanistic drug approaches combined with ways to improve trial execution. This review summarizes the known phenotype and pathophysiology of FXS and past clinical trial rationale and results, and discusses current challenges facing the field and lessons from which to learn for future treatment development efforts.

KW - Drug development

KW - Fragile X syndrome

KW - Genetic disorder

KW - Targeted treatments

KW - Translational treatment

UR - http://www.scopus.com/inward/record.url?scp=85020725021&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85020725021&partnerID=8YFLogxK

U2 - 10.1186/s11689-017-9186-9

DO - 10.1186/s11689-017-9186-9

M3 - Review article

VL - 9

JO - Journal of Neurodevelopmental Disorders

JF - Journal of Neurodevelopmental Disorders

SN - 1866-1947

IS - 1

M1 - 7

ER -